Onward Therapeutics Announces Enrollment of Phase 1 Clinical Trial of a Novel Bispecific Antibody (OT-A201) Targeting Two Immune Checkpoints

Onward Therapeutics SA announced that the phase 1 clinical trial of OT-A201, a first-in-class bispecific antibody targeting two immune checkpoints is in progress.